This warning letter, issued on May 18, 2021, addresses concerns about this company’s marketing of kratom and other pharmaceutical and nutritional supplement products. The letter outlines
On May 15, 2020, the U.S. Food and Drug Administration (FDA) issued a warning letter to The Golden Road Kratom regarding violations related to the marketing
On July 3, 2023, the U.S. Food and Drug Administration (FDA) issued a warning letter to Sunshine Trading Company, Inc., operating as Nova Tea and Nova
This document serves as a formal warning issued to Shot of Joy LLC on September 25, 2023, addressing concerns related to non-compliance with regulatory standards and
This document examines the FDA warning letter issued to Revibe, Inc. on May 18, 2018, highlighting the regulatory concerns raised regarding the company’s marketing and manufacturing
On June 30, 2022, the FDA and FTC jointly issued warning letters to four companies, including Omni Consumer Products LLC, doing business as YoKratom, regarding the
This warning letter, issued to Mitra Distributing Inc. on September 4, 2018, addresses compliance issues identified during a recent inspection. The letter outlines specific violations of
On May 16, 2019, the U.S. Food and Drug Administration (FDA) issued a Warning Letter to KratomNC, highlighting significant concerns regarding the marketing and safety of
On May 18, 2018, the U.S. Food and Drug Administration (FDA) issued a warning letter to Kratom Spot, a retailer of kratom products, addressing significant regulatory
This warning letter, issued on May 18, 2021, addresses concerns about this company’s marketing of kratom and other pharmaceutical and nutritional supplement products. The letter outlines
On May 15, 2020, the U.S. Food and Drug Administration (FDA) issued a warning letter to The Golden Road Kratom regarding violations related to the marketing
On July 3, 2023, the U.S. Food and Drug Administration (FDA) issued a warning letter to Sunshine Trading Company, Inc., operating as Nova Tea and Nova
This document serves as a formal warning issued to Shot of Joy LLC on September 25, 2023, addressing concerns related to non-compliance with regulatory standards and
This document examines the FDA warning letter issued to Revibe, Inc. on May 18, 2018, highlighting the regulatory concerns raised regarding the company’s marketing and manufacturing
On June 30, 2022, the FDA and FTC jointly issued warning letters to four companies, including Omni Consumer Products LLC, doing business as YoKratom, regarding the
This warning letter, issued to Mitra Distributing Inc. on September 4, 2018, addresses compliance issues identified during a recent inspection. The letter outlines specific violations of
On May 16, 2019, the U.S. Food and Drug Administration (FDA) issued a Warning Letter to KratomNC, highlighting significant concerns regarding the marketing and safety of
On May 18, 2018, the U.S. Food and Drug Administration (FDA) issued a warning letter to Kratom Spot, a retailer of kratom products, addressing significant regulatory
The Kratom Research Institute was established to create a trusted hub for kratom-related information. We are a non-partisan organization focused solely on delivering facts, studies, and news, without promoting or opposing the use of kratom. Our goal is to offer a clear, objective view of the current state of kratom research, regulations, and public discourse.
We understand that kratom is a topic of debate, and that’s why we take a balanced approach—presenting information from all sides so you can make informed decisions based on credible sources.
